IDBiologics, founded in 2017, specializes in the discovery and development of human monoclonal antibodies aimed at preventing, treating, and curing infectious diseases. The company leverages a proprietary fully human monoclonal antibody platform, which enables the rapid discovery and optimization of broad and potent therapeutic molecules. This platform has allowed IDBiologics to build a comprehensive portfolio of antibodies targeting a wide range of both commercial and emerging infectious diseases. The company collaborates with institutions like Vanderbilt University Medical Center to accelerate the development of breakthrough medicines, particularly highlighted by their efforts against COVID-19. IDBiologics operates in the biopharmaceutical market, serving healthcare providers and research institutions. The business model focuses on the development and commercialization of its antibody therapies, generating revenue through partnerships, licensing agreements, and direct sales of its products.

Keywords: monoclonal antibodies, infectious diseases, biopharmaceutical, COVID-19, therapeutic molecules, Vanderbilt University, healthcare, research institutions, commercialization, antibody therapies.